GenoMed, Inc. Licenses Treatment Regimen to La Clinica
ST. LOUIS, May 23 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that it has signed an agreement to license its ACE inhibitor treatment regimen to La Clinica, a free medical clinic serving the Hispanic population of St. Louis. Terms of the Licensing Agreement were not disclosed.
La Clinica is a rapidly growing medical clinic that was founded in 1993 to serve the healthcare needs of the Latino community in the St. Louis area. GenoMed's treatments will be administered to La Clinica patients under the close supervision of GenoMed.
Large pharmaceutical companies such as Pfizer and Bristol-Myers Squibb already donate prescription drugs to La Clinica for use by La Clinica's patients. The physicians and medical students seeing patients at La Clinica all volunteer their time.
Dr. William Chignoli, founder and Executive Director at La Clinica, stated that, "GenoMed's drug regimen appears to delay and, if taken early enough, even prevent complications of diabetes and hypertension. GenoMed's patient outcomes data are superior to anything that I have read in the medical literature to date." Dr. Chignoli further commented, "The need for such a treatment is especially great in this patient population. Almost half of our patients have type 2 diabetes, and it affects them at a much earlier age than the Caucasian population. There is little money available for surgery or hospitalization for these patients, so the best approach is to keep them healthy. GenoMed's treatment is helping to accomplish this."
David W. Moskowitz, GenoMed's Chairman and Chief Medical Officer will initially oversee the administration of the treatment regimen at La Clinica.
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. A recent St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) reported that the company has applied for patents based on its finding that the ACE gene is associated with nearly 40 common, age-related diseases. The Company has filed patent applications on its new treatments for both human and veterinary use. A video version of the company's treatment results for chronic kidney failure is available at 216.234.225.2
Consistent with the Company's goal to improve patient outcomes globally, GenoMed is currently working to license its treatments to physicians and healthcare systems worldwide.
A GenoMed press conference will be held at La Clinica Health Center (3646 Fairview Ave., St. Louis, MO; tel. 314-664-5565) on Thursday, May 23, 2002 immediately following Lieutenant Governor Joe Maxwell's press conference introducing the Missouri Senior Rx Program, to be held at the same location.
For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX 314-977-0042, email: kfischer@genomedics.com, or visit GenoMed at www.genomedics.com.
SOURCE GenoMed, Inc.
CONTACT: Krissy Fischer of Genomed, Inc., +1-877-436-6633, or fax,
+1-314-977-0042, or kfischer@genomedics.com
Web site: genomedics.com
. |
